L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?
|
|
- Alexander Brown
- 6 years ago
- Views:
Transcription
1 L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active? Thierry Vander Borght UCL Mont-Godinne, Belgique
2
3 FDG-PET in Lymphoma: Mont-Godinne Experience 03/ /2002: 199 FDG-PET in lymphomas: 43 initial staging 53 early assessment of treatment response 103 follow-up 90 NHL and 11 HD
4 Case #1: Mrs M.G. 68 years 12/98 Diagnosis: transformed follicular NHL Stage: I R/ CHOP x4 + RT Result: CR1 03/01 jugal tumefaction and cervical nodes Relapse? FDG-PET
5 March 2001 Giant cells
6 Shah & Branstetter. Oncocytoma of the parotid gland: a potential falsepositive finding on FDG PET. AJR 2007;189:W (SUV 6.2) Bilaterally symmetrical increased uptake is usually physiological An asymmetrical uptake, especially when focal, would warrant correlation Nucl Med Commun 2008;29(4):
7
8 CL360517
9 Buchler et al. SM. Haematologica 2007;92:120-1.
10 Retrospective study of patients with nonlung cancer: 103/933 (11%) hilar FDG-avid foci Univariate analysis variables associated with malignancy SUV max (6.6 vs. 3.5 for benign) Impurity = non hilar chest foci (79% vs. 18% for benign) Node size on CT Δ uptake between scans 1 and 2 (2.7 vs. 0.73) Variables associated with benign Symmetry Purity Colorectal primary (75% = benign vs. 34 breast, 49 lymphoma, 37 others) Multivariate analysis SUV max (odds of malignancy by 1.54 for each unit increase in SUV) Purity (odds of malignancy by 0.08 if pure). J Nucl Med 2008;49:
11 Brepoels L, et al. Leuk Lymphoma 2007;48:
12 Cervical thymic hyperplasia after chemotherapy in an adult patient with HL: a potential cause of FP on FDG PET/CT scanning Fallanca et al. Br J Haematol 2008;140:477.
13 Lipomatous Hypertrophy Interatrial Septum 1% at autopsy, 2-8% on echo Increase in size with age Associated with arrhythmias Increased uptake on FDG-PET Mixed fat, brown fat and fibrous tissue on histology Fan et al. Am J Roentgenol 2005;184:
14 MA 62 y-old man A A B C B C A B C
15 Case #2: Mr J.J., 64 years Diagnosis: stage IV (lung) DLBCL 08/00 3 CHOP 10/00
16 6 m. FU Transbronchic biopsy PAS Invasive aspergillosis
17 28-year-old man History of Hodgkin disease in remission Fatigue, pyrexia, and a raised ESR Sheehy N, et al. Clin Nucl Med 2007;32:820-1.
18 Case report #3: Mr B.E. 55 years 1994 Diagnosis: Peripheral T-cell NHL 40 x CD3 Stage: III B Treatment: Result: CR1 ACVBP x4 + conso 2000 Relapse: salvage CT: Edx-Vp16 x1/ VIM2AraC x2 Staging before intensification: CR2?
19 March 2000 At relapse July 2000 Before PBSCT en s é Pr n it o ta M A R P A EN
20 SUV = 4 SUV = 1.8 March 2000 At relapse July 2000 Before PBSCT en s é Pr n it o ta M A R P A EN
21 Transbronchic biopsy and bone biopsy SUV = x September months after PBSCT Non small cell carcinoma
22 Case report #4: Mr G.H. 71 years 1989 Diagnosis: Diffuse large B-cell NHL Stage : III B Treatment: Alt VIM/ACVBP x4 Result: CR Relapse: Clinical stage: I : inguinal lymph node PET stage: III Treatment: CHOP x4 + RTh Result: CR2
23 02/00 Relapse? 04/01 End R/ 05/02 FU
24 02/00 Relapse? DLBCL 04/01 End R/ 20 x HE 05/02 FU M A R P A EN n it o NSCLC ta 20 x HE n e s é Pr
25 Case report #5: Mr D.J. 53 years 1990 Diagnosis: Hodgkin s disease Stage: I Treatment: surgery + Rth Result: CR1 2000: cervical lymph node FDG-PET
26 Epidermoid carcinoma of unknown origin 4 x HE
27 Case report n 6: Mrs C.B. 67 years 1999 Diagnosis: lymphocytic lymphoma Stage: IV R/ chlorambucil CR1 December 2001: FU FDG-PET Rectal villous tumour
28 Tatlidil et al. Radiology 2002;224: /06-02/07: selection of patients with unusual bowel uptake 14% colonic malignancy 38% polyps, gastrointestinal stromal tumour and severe ulcerative colitis Gupta & Olson. RSNA 2008: SSJ21-04
29 CT corrected PET image Ge corrected PET image Subtraction PET image CT transmission image Ge transmission image CT scan Nakamoto et al. Nucl Med Commun 2004;25:
30 Mantle Cell Lymphoma 59-year-old man Fatigue, weight loss Clinical exam: splenomegaly, adenopathies Inguinal node biopsy BMB: cyclin D1 overexpression [t(11;14)] 27/01/2003; HY modified from Lenz G et al. Ann Hematol 2004;83:
31 Summary Initial D/ Time Interval Secondary D/ Non-malignant lesions B-NHL 27 months Sarcoidosis B-NHL 6 months Aspergillosis X = 16.5 months Malignant lesions T-NHL 70 months NSCLC B-NHL 154 months NSCLC Hodgkin 116 months Epidermoid carcinoma B-NHL 31 months Villous tumour B-NHL 63 months SCLC X = 70 months
32 2837 agressive NHL from 02/84 to 01/87 81 second cancers = 66 (17 hematologic; 49 solid [21 lung]) 7-year cumulative incidence = 2.75% Blood. 2004;103:
33 Conclusion These data illustrate the role of FDG-PET in (re)staging of lymphoma Relapse suspected only on FDG-PET imaging requires biopsy as alternative diagnoses are possible Early in the follow-up, persistent abnormal FDG uptake in sites unrelated to the initial staging is highly suspicious for infection, whereas later, new lesion is suspicious of secondary tumour FDG-PET might be a new modality for long-term monitoring of late effects, especially second cancer occurrence
34 Merci pour votre attention
35 Ceci est-il un lymphome? Merci pour votre attention
PET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationStaging: Recommendations for bone marrow investigations
International Workshop for PET in Lymphoma Staging and Restaging Thursday October 4th, Menton. Staging: Recommendations for bone marrow investigations Martin Hutchings Department of Haematology Rigshospitalet,
More informationSarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma
Sarajevo (Bosnia Hercegivina) Monday June 16 2013 15:30-16:15 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early assessment during treatment / interim (ipet) Remission
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More information4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012
4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012 international workshop for PET in lymphoma staging and restaging Lale Kostakoglu Department of Radiology Mount
More informationBilateral hilar 18 F-FDG avid foci are often noted on
Bilateral Hilar Foci on F-FDG PET Scan in Patients Without Lung Cancer: Variables Associated with Benign and Malignant Etiology Maroun Karam 1, Shayna Roberts-Klein 1, Narendra Shet 2, Johanna Chang 2,
More informationThe Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.
The Importance of PET/CT in Human Health Homer A. Macapinlac, M.D. Learning objectives Provide an overview of the impact of PET/CT imaging on the management of patients and its impact on health care expenditures.
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationPET/CT and PET/MR of Cardiac Tumors
PET/CT and PET/MR of Cardiac Tumors Andrew W. Bowman, MD PhD Assistant Professor of Radiology Mayo Clinic Florida NASCI Annual Meeting San Antonio, TX Oct 9, 2017 2017 MFMER slide-1 Disclosures No financial
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationFalse Positive Imaging in PET-CT: When CT makes the difference Case-based
False Positive Imaging in PET-CT: When CT makes the difference Case-based L. Lepore (1), MD; S. Rossi (1, 2), MD; MV. Ramos (1), MD; V. Rubio (1), MD; V. Soroa (1), MD; M. Volpacchio (1), MD (1) Centro
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationPros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen
3rd International Workshop on in Lymphoma Menton, September 26, 2011 Afternoon Controversies Pros and Cons: in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen Pros Is there any
More informationRyan Niederkohr, M.D. Slides are not to be reproduced without permission of author
Ryan Niederkohr, M.D. CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet) SELECTING FIELD
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationTesticular relapse of non-hodgkin Lymphoma noted on FDG-PET
Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET Stephen D. Scotti 1*, Jennifer Laudadio 2 1. Department of Radiology, North Carolina Baptist Hospital, Winston-Salem, NC, USA 2. Department of
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationNuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationClinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.
Clinical summary Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT. For restaging PET/CT. PET/CT findings No significant FDG uptake
More informationFDG-PET/CT in the management of lymphomas
FDG-PET/CT in the management of lymphomas Olivier Gheysens, MD, PhD Dept. of Nuclear Medicine, UZ Leuven BHS, Feb 4th 2017 Brussels Dept. of Nuclear Overview Introduction on FDG-PET/CT Staging Response
More informationIntegrating FDG PET data for lymphoma management. Michel Meignan, France
Integrating FDG PET data for lymphoma management Michel Meignan, France Combining metabolic data from baseline, interim or post treatment PET PET Data can be combined: 1. Together 2. With baseline clinical
More informationPET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging
Basics of PET/CT Imaging Kevin Robinson, DO Department of Radiology Michigan State University Objectives Basic PET imaging Evaluating the therapeutic response Evaluating the big 5 Lymphoma Breast Lung
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationYiyan Liu. 1. Introduction
AIDS Research and Treatment Volume 2012, Article ID 764291, 6 pages doi:10.1155/2012/764291 Clinical Study Concurrent FDG Avid Nasopharyngeal Lesion and Generalized Lymphadenopathy on PET-CT Imaging Is
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationAssessing the lung and mediastinum in cancer-is tissue the issue? George Santis
1 Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis Optimal management of Cancer Histological diagnosis & accurate staging at presentation Molecular analysis of primary tumour
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationPositron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 16, Number 4, 2001 Mary Ann Liebert, Inc. Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL) F. Najjar, R. Hustinx, G.
More informationSally Barrington Martin Hutchings
Sally Barrington Martin Hutchings Therapeutic implications of BMI Bone marrow involvement means extranodal disease and by definition stage IV BMI detected by BMB is a poor prognostic feature in most lymphomas
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationBoot Camp Case Scenarios
Boot Camp Case Scenarios Case Scenario 1 Patient is a 69-year-old white female. She presents with dyspnea on exertion, cough, and right rib pain. Patient is a smoker. 9/21/12 CT Chest FINDINGS: There is
More informationLung hilar Ga-67 uptake in patients with lymphoma following chemotherapy
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 5, 391 397, 2004 Lung hilar Ga-67 uptake in patients with lymphoma following chemotherapy Emel Ceylan GUNAY,* Bilge Volkan SALANCI,* Ibrahim BARISTA**
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationPET/CT for Therapy Assessment in Oncology
PET/CT for Therapy Assessment in Oncology Rodolfo Núñez Miller, M.D. Nuclear Medicine Section Division of Human Health International Atomic Energy Agency Vienna, Austria Clinical Applications of PET/CT
More informationPositron Emission Tomography in the Evaluation of Lymphoma
Positron Emission Tomography in the Evaluation of Lymphoma Ora Israel, Zohar Keidar, and Rachel Bar-Shalom Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) has emerged in recent years
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationProgramming LYRIC Response in Immunomodulatory Therapy Trials Yang Wang, Seattle Genetics, Inc., Bothell, WA
PharmaSUG 2017 Paper BB12 Programming LYRIC Response in Immunomodulatory Therapy Trials Yang Wang, Seattle Genetics, Inc., Bothell, WA ABSTRACT The LYmphoma Response to Immunomodulatory therapy Criteria
More informationImaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT
AJR Integrative Imaging LIFELONG LEARNING FOR RADIOLOGY Imaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT Hima B. Prabhakar 1, Chad B. Rabinowitz 1, Fiona K. Gibbons 2, Walter J. O Donnell 2,
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationUtility of FDG PET/CT in the Assessment of Myeloid Sarcoma
Nuclear Medicine and Molecular Imaging Pictorial Essay Nuclear Medicine and Molecular Imaging Pictorial Essay Elaine Yuen Phin Lee 1 Marina-Portia nthony 1 nskar Yu-Hung Leung 2 Florence Loong 3 Pek-Lan
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationRecommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas
Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA Disclosures
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT LYMPHOMA CHAPTER 11B REVISED: SEPTEMBER 2016
LYMPHOMA Definitions of Response According to Non Hodgkin s Lymphoma (NHL) Criteria Listed below is the new NCI Lymphoma criteria for evaluation and endpoint definitions for Non Hodgkin s Lymphoma response
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationWorkshop key imaging questions
11th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland, June 15-18, 2011 Workshop key imaging questions Relevance of current imaging staging systems Influence of tumour burden Need for
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationHigh incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens
original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationDiffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy
Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy Poster No.: C-1785 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationMRI in lymphoma: where are we in 2016
MRI in lymphoma: where are we in 2016 Alain Rahmouni Henri Mondor Academic Hospital Paris Est Créteil University, France Plan Requirements DWI signal in lymphoma ADC measurement SNR: Surface coils 1.5
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationPatient underwent hemicolectomy: 7 x 4.5 cm intusscepted segment of ileum in colon - mucosal
Extranodal Lymphomas Rena Buckstein Odette Cancer Center Case: JT 69 yo male COO software company PMHx: basal cell back, cholesterol Presents to ER with severe abdominal pain, bloody diarrhea x 2d In ER
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationSEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
More informationDiagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis)
Diagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis) Sevda Sener Cömert, MD, FCCP. SBU, Kartal Dr.Lütfi Kırdar Training and Research Hospital Department of Pulmonary
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationSubject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:
Subject: PET Scan With or Without CT Attenuation Policy Number: MCR: 610 Revision Date(s): MHW Original Effective Date: 11/7/2017 Review Date: DISCLAIMER This Molina Clinical Review (MCR) is intended to
More informationPediatric Lymphoma Update from the Children s Oncology Group
Pediatric Lymphoma Update from the Children s Oncology Group Stephan D. Voss, MD, PhD Department of Radiology Boston Children s Hospital Harvard Medical School Staging Assessment Disclosures None Acknowledgements:
More informationDeppen S, et al. Annals of Thoracic Surgery 2011;92:
Deppen S, et al. Annals of Thoracic Surgery 2011;92:428-33. http://www.nationmaster.com/graph/ mor_his-mortality-histoplasmosis http://www.humirarems.com/brochure.aspx Baddley, John W., et al. Emerging
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationPositron emission tomography detection of synchronous colon cancer in a patient with chronic lymphocytic leukemia
LETTER TO THE EDITOR Korean J Intern Med ;8:- Positron emission tomography detection of synchronous colon cancer in a patient with chronic lymphocytic leukemia Jeong Eun Lee, Sang Mook Bae, Moon Sung Kim,
More informationSCBT-MR 2015 Incidentaloma on Chest CT
SCBT-MR 2015 Incidentaloma on Chest CT Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report Incidentaloma Pulmonary Nodule Mediastinal Lymph Node Coronary Artery Calcium Incidental
More informationAbstracting Hematopoietic Neoplasms
CASE 1: LYMPHOMA PHYSICAL EXAMINATION 43yo male with a history of lower gastrointestinal bleeding and melena undergoing colonoscopy and biopsy to rule out neoplasm versus inflammation. Patient had no other
More informationImaging techniques in the diagnosis, staging and follow up of GI cancers. Moderators: Banke Agarwal, MD and Paul Schultz, MD
Imaging techniques in the diagnosis, staging and follow up of GI cancers Moderators: Banke Agarwal, MD and Paul Schultz, MD Panelists Axel Grothey, MD Professor of Oncology Division of Medical Oncology
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationInfection Imaging In Nuclear Medicine: Arguing The Case for PET/CT.
Infection Imaging In Nuclear Medicine: Arguing The Case for PET/CT. LUIS A. TAMARA M.D. NUCLEAR MEDICINE /PET-CT SERVICE CHIEF MEDVAMC DISCLOSURES. 2 3 Not difficult to appreciate the difference! GA-67
More information42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%
Pinhole images of the neck are acquired in multiple projections, 24hrs after the oral administration of approximately 200 µci of I123. Usually, 24hr uptake value if also calculated (normal 24 hr uptake
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationEuropean evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management
European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management J. Martin-Comin Hospital U. Bellvitge Hospitalet de Llobregat Spain THE EUROPEAN
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationIntroduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
More informationStrikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era
Research Article Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era Irit Avivi, 1,2 * Ariel Zilberlicht, 1 Eldad J.
More informationNK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationThe solitary pulmonary nodule: Assessing the success of predicting malignancy
The solitary pulmonary nodule: Assessing the success of predicting malignancy Poster No.: C-0829 Congress: ECR 2010 Type: Scientific Exhibit Topic: Chest Authors: R. W. K. Lindsay, J. Foster, K. McManus;
More information